000210663 001__ 210663
000210663 005__ 20230208173807.0
000210663 0247_ $$2CORDIS$$aG:(EU-Grant)730983$$d730983
000210663 0247_ $$2CORDIS$$aG:(EU-Call)H2020-INFRAIA-2017-1-two-stage$$dH2020-INFRAIA-2017-1-two-stage
000210663 0247_ $$2originalID$$acorda__h2020::730983
000210663 035__ $$aG:(EU-Grant)730983
000210663 150__ $$aINfraStructure in Proton International REsearch$$y2018-03-01 - 2022-12-31
000210663 371__ $$aIon Beam Applications (Belgium)$$bIon Beam Applications (Belgium)$$dBelgium$$vCORDIS
000210663 371__ $$aTHE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS, POLISH ACADEMY OF SCIENCES$$bIFJ PAN$$dPoland$$ehttp://www.ifj.edu.pl$$vCORDIS
000210663 371__ $$aAarhus University$$bAU$$dDenmark$$ehttp://www.au.dk/en/$$vCORDIS
000210663 371__ $$aTHE CHRISTIE NHS FOUNDATION TRUST$$bTHE CHRISTIE$$dUnited Kingdom$$ehttp://www.christie.nhs.uk$$vCORDIS
000210663 371__ $$aPaul Scherrer Institute$$bPSI$$dSwitzerland$$ehttp://www.psi.ch/$$vCORDIS
000210663 371__ $$aINTERNET-SIMULATION EVALUATION ENVISION SRL$$bI-SEE$$dItaly$$ehttp://www.i-seecomputing.com$$vCORDIS
000210663 371__ $$aUSTAV JADERNE FYZIKY AV CR$$bNUCLEAR PHYSICS INSTITUTE OF THE CAS VVI$$dCzech Republic$$ehttp://www.ujf.cas.cz$$vCORDIS
000210663 371__ $$aKOMMUNALFORBUNDET AVANCERAD STRALBEHANDLING$$dSweden$$ehttp://www.skandionkliniken.se$$vCORDIS
000210663 371__ $$aVARIAN MEDICAL SYSTEMS PARTICLE THERAPY GMBH$$dGermany$$ehttps://www.varian.com/oncology/solutions/proton-therapy$$vCORDIS
000210663 371__ $$aACADEMISCH ZIEKENHUIS GRONINGEN$$bUNIVERSITAIR MEDISCH CENTRUM GRONINGEN$$dNetherlands$$ehttp://www.umcg.nl$$vCORDIS
000210663 371__ $$aTU Dresden$$bTUD$$dGermany$$ehttp://tu-dresden.de/en$$vCORDIS
000210663 371__ $$aUNIVERSITE DE NAMUR ASBL$$bUNamur$$dBelgium$$ehttp://www.unamur.be$$vCORDIS
000210663 371__ $$aInstitute Curie$$bInstitute Curie$$dFrance$$ehttp://www.institut-curie.org/$$vCORDIS
000210663 371__ $$aGSI Helmholtzzentrum für Schwerionenforschung GmbH$$bGSI$$dGermany$$ehttp://www.gsi.de/$$vCORDIS
000210663 371__ $$aUniversity of Manchester$$bUniversity of Manchester$$dUnited Kingdom$$ehttp://www.manchester.ac.uk/$$vCORDIS
000210663 371__ $$aNational Institute for Nuclear Physics$$bINFN$$dItaly$$ehttp://www.infn.it/index.php?lang=en$$vCORDIS
000210663 371__ $$aUniversity of Groningen$$bUniversity of Groningen$$dNetherlands$$ehttp://www.rug.nl/$$vCORDIS
000210663 371__ $$aLIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS$$bLSMU$$dLithuania$$ehttp://www.lsmuni.lt$$vCORDIS
000210663 372__ $$aH2020-INFRAIA-2017-1-two-stage$$s2018-03-01$$t2022-12-31
000210663 450__ $$aINSPIRE$$wd$$y2018-03-01 - 2022-12-31
000210663 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000210663 680__ $$aProton beam therapy (PBT) is a radical new type of advanced radiotherapy, capable of delivering and conforming a targeted dose of radiation to the tumour while causing minimal damage to the surrounding healthy tissue. In the past 5 years there has been a huge investment in high energy PBT across Europe and eleven member states now either have PBT in operation or are developing this capability.  In addition, the two largest manufactures of PBT equipment have based their manufacturing in Europe. This integrating activity INSPIRE, aims to link these clinical PBT centres in eleven different countries together with two associated centres in USA.  It also brings in two of the worlds largest manufacturers of PBT equipment and an SME.  The trans-national access in INSPIRE will provide European researchers with access to “state of the art” research capabilities employing proton beams at clinical energies.  INSPIRE represents an integrating activity across Europe in a multi-disciplinary field that is growing exponentially. 
Through its Networking, Transnational Access and Joint Research Activities,  INSPIRE seeks to provide the “state of the art” capabilities that are needed to address the key challenges in this rapidly developing field. INSPIRE has at its heart the principles of responsible research and innovation and will communicate its research and give access to its databases and software through an Open Access Gateway.  INSPIRE will contain a pipeline of innovation through its Innovation Gateway, to accelerate research for patient and commercial benefit.  INSPIRE will provide its researchers with an unrivalled research and training and opportunities to “discipline hop” into the industrial, clinical or industrial environment.  INSPIRE integrates activities across Europe in this rapidly growing area and offers European researchers unrivalled access to state of the art research capabilities in an area where there has already been significant government investment.
000210663 909CO $$ooai:juser.fz-juelich.de:846754$$pauthority$$pauthority:GRANT
000210663 909CO $$ooai:juser.fz-juelich.de:846754
000210663 970__ $$aoai:dnet:corda__h2020::3e809f48564a76a1394b584892446443
000210663 980__ $$aG
000210663 980__ $$aCORDIS
000210663 980__ $$aAUTHORITY